B. Riley FBR Maintains Buy on Arbutus Biopharma, Raises Price Target to $6

B. Riley FBR maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and raises the price target from $3 to $6.

Benzinga · 01/09/2020 18:35

B. Riley FBR maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and raises the price target from $3 to $6.